Phase IV randomized, single-blind clinical trial with three parallel arms to compare ovulation triggering strategies in IVF cycles with fresh embryo transfer.
Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospital Clinico De Valencia-INCLIVA
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Reproductive and Urinary Physiological Phenomena
Decision date
13/07/2026
Enrollment target
126
Sites
Spain
Condition studied
Women with infertility and low ovarian reserve.
Investigational medicinal product(s)
Orgalutran 0.25 mg/0.5 mL solution for injectionDecapeptyl diario 01 mg polvo y disolvente para solución inyectableREKOVELLE 72 micrograms/2.16 mL solution for injection in a pre-filled penOrgalutran 0.25 mg/0.5 mL solution for injectionREKOVELLE 36 micrograms/1.08 mL solution for injection in a pre-filled penOrgalutran 0.25 mg/0.5 mL solution for injectionOvitrelle 250 micrograms solution for injection in pre-filled penOvitrelle 250 micrograms solution for injection in pre-filled penOrgalutran 0.25 mg/0.5 mL solution for injectionOrgalutran 0.25 mg/0.5 mL solution for injectionOrgalutran 0.25 mg/0.5 mL solution for injectionREKOVELLE 36 micrograms/1.08 mL solution for injection in a pre-filled penREKOVELLE 36 micrograms/1.08 mL solution for injection in a pre-filled penMeriofert Kit 900 UI polvo y disolvente para solución inyectableOrgalutran 0.25 mg/0.5 mL solution for injectionREKOVELLE 36 micrograms/1.08 mL solution for injection in a pre-filled penREKOVELLE 72 micrograms/2.16 mL solution for injection in a pre-filled penREKOVELLE 72 micrograms/2.16 mL solution for injection in a pre-filled penOvitrelle 250 micrograms solution for injection in pre-filled penREKOVELLE 72 micrograms/2.16 mL solution for injection in a pre-filled penOrgalutran 0.25 mg/0.5 mL solution for injectionOvitrelle 250 micrograms solution for injection in pre-filled pen
Eligibility
Age group
18-64 years
Sex
Female
Primary endpoint
Number of metaphase II (MII) oocytes retrieved at oocyte pickup.
Endpoint detail
Proportion of mature oocytes (MII/total oocytes)., Biochemical pregnancy rate and ongoing pregnancy rate., Gene expression of receptors and enzymes involved in folliculogenesis and ovarian steroidogenesis in mature oocytes.
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.